Skip to main content

Table 2 Response to imatinib: (n = 87; n = 8 not assessable).

From: Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial

  N pts (%)
Complete Response 4 (4.6)
Partial Response 26 (29.9)
Stable disease 41 (47.1)
Progressive disease 16 (18.4)